NHS Framework Agreement, Branded Medicines for London and South of England

NHS Framework Agreement, Branded Medicines for London and South of England Offer reference number: CM/PHR/20/5598 FIND A TENDER (FTS) Reference number: FTS-002229 CM/PHR/20/5598/01 - NHS Framework for LONDON Branded Medicines - Tranche B. Period of framework: 1 September 2021 to 31 August 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months CM/PHR/20/5598/02 - NHS Framework for the LONDON Branded Medicines - Annual Tranche. Period of framework: 1 September 2021 to 31 August 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months CM/PHR/20/5598/03 - NHS Framework for the SOUTH of England Tranche A. Period of Framework: 1 September 2021 to 31 August 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months CM/PHR/20/5598/04- NHS Framework for SOUTH of England - Tranche B. Period of framework: 1 September 2021 to 31 August 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months CM/PHR/20/5598/05 - NHS Framework for the SOUTH of England Annual Tranche. Period of Framework: 1 September 2021 to 31 August 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months CM/PHR/20/5598/06 - NHS Framework for the Midlands & East and North of England Regions - Bevacizumab Period of Framework: 1 September 2021 to 28 February 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 6 months